Financial Guidance and Company Overview
Transaction Rationale Summary
Strategic Fit
Risk Profile
•
Differentiated auto injector platform that can be licensed widely and potentially extend to higher
volume auto injectors
Ability to leverage existing U.S. commercial infrastructure to promote proprietary products with
substantial growth trajectory
De-risked platform with a suite of approved commercial products (wholly owned and partnered)
Revenue
Opportunity
Proven Track Record of
Commercial Success
Financial Fit
Halozyme
Multiple Opportunities:
Existing small volume auto injector technology
•
Potential to extend to high volume, up to 5.0mL
Commercial products (XYOSTED®, TLANDOTM, NOCDURNAⓇ)
Meaningful opportunity for increased revenues and expansion into additional, high revenue segments
Expected to be immediately accretive to revenue and non-GAAP EPS accretion with multiple drivers
to augment growth post 2027
16View entire presentation